Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: solithromycin Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin

NCT02348424
View directory record Official record
Conditions
Gonorrhoea
Interventions
Solithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Sep 2, 2026, 6:32 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01168713
View directory record Official record
Conditions
Community-Acquired Bacterial Pneumonia
Interventions
Levofloxacin, CEM-101
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
45
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Bell Gardens, California + 41 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 2, 2026, 6:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea

NCT01591447
View directory record Official record
Conditions
Uncomplicated Urogenital Gonorrhea
Interventions
solithromycin, Solithromycin (CEM-101)
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
19 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 2, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea

NCT02210325
View directory record Official record
Conditions
Uncomplicated Urogenital Gonorrhea
Interventions
solithromycin, ceftriaxone, azithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
15 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Baltimore, Maryland • Cleveland, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2017 · Synced Sep 2, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents

NCT01966055
View directory record Official record
Conditions
Bacterial Infections
Interventions
Solithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Little Rock, Arkansas • San Diego, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 2, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics and Safety of Solithromycin in Adolescents and Children

NCT02268279
View directory record Official record
Conditions
Bacterial Infection
Interventions
solithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
Up to 17 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
31
States / cities
Little Rock, Arkansas • Orange, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Sep 2, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01968733
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
62
States / cities
Mobile, Alabama • Little Rock, Arkansas • Chino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 2, 2026, 6:32 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01756339
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Moxifloxacin, Placebo to match solithromycin
Drug · Other
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Glendale, California • Los Angeles, California • Mission Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 2, 2026, 6:32 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis

NCT02510599
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
solithromycin
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Sep 2, 2026, 6:32 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

NCT02605122
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Standard of Care
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 2, 2026, 6:32 PM EDT